#Singapore #Bridge to Life #ILTS 2025 #HOPE Technology

Bridge to Life Presents Abstracts at ILTS 2025

Bridge to Life™ Ltd., a premier provider of organ preservation solutions and perfusion technology, has made headlines with its announcement regarding the upcoming 2025 International Congress of the International Liver Transplantation Society (ILTS). Scheduled from May 28 to May 31 in Singapore, this significant event will see the company presenting nine accepted abstracts, including two late-breaking studies that shine a spotlight on advancements in liver transplantation.

Overview of Presentations

The focus will be on Hypothermic Oxygenated Perfusion (HOPE), a cutting-edge technology that has significant implications for liver transplants, especially in pediatric cases. The abstracts discuss various aspects of this technology, showcasing its potential benefits across various scenarios:

1. Late Breaker: Impact of Machine Perfusion on Ischemia-Reperfusion Injury in Liver Transplantation: A Donor Age-Stratified Analysis - This study examines how machine perfusion can mitigate injury during liver transplantation, particularly considering the age of donors.
2. Late Breaker: Machine Perfusion in Liver Transplantation: A Game Changer for Middle-Volume Centers? - A discussion on the viability of machine perfusion as a solution for centers that may not handle high volumes of transplants.
3. Use of HOPE Machine Perfusion for Transplantation in Unusual Scenarios - A case report depicting successful outcomes using HOPE in unique transplant situations.
4. Hypothermic Oxygenated Perfusion (HOPE) in Pediatric Liver Transplantation: Preliminary Results - An examination of how HOPE influences pediatric liver transplants.
5. HOPE for Hepatocellular Carcinoma - Analyzing recurrence rates in patients who have undergone transplantation with grafts treated using HOPE.
6. The Impact of HOPE on Liver Transplantation for ACLF and ALF - A promising perspective on how HOPE could improve outcomes in severe liver failure cases.
7. Results of Implementation of Hypothermic Oxygenated Perfusion (HOPE) for Human Liver Grafts - Insights from a tertiary hospital’s experience with HOPE.
8. HOPE for Combined Heart and Liver Transplant - Findings on the applicability of HOPE in combined organ transplants.
9. HOPE for the Hopeless Grafts: Experience from a Single Center - A report on outcomes from centers using HOPE for less favorable grafts.

The presentations aim to contribute significantly to the body of knowledge surrounding liver transplantation and HOPE technology.

Additional Activities

In addition to the presentations, Bridge to Life will actively participate in a practical workshop focused on liver perfusion, designed for hands-on experiences. This session is scheduled for May 28, 2025. Attendees will need to pre-register for the 5th ILTS Hands-on Liver Machine Perfusion Workshop to secure their participation.

Furthermore, a symposium titled “Expanding the Boundaries of Hypothermic Oxygenated Perfusion: Addressing Challenges and Opportunities in the Asia-Pacific Region” will be held on May 29 at 3 PM SST. Esteemed speakers will include Dr. Sonal Asthana from Aster Hospitals, Dr. Andrea Schlegel from the Cleveland Clinic, and Dr. Rebeca Sanabria Mateos from Queen Elizabeth Hospital in Birmingham.

About Bridge to Life™ Ltd.

Bridge to Life™ Ltd. stands at the forefront of organ preservation solutions, providing essential products like Belzer UW®, EasiSlush®, and the VitaSmart™1 Hypothermic Oxygenated Perfusion System. With a commitment to innovation and quality, the company collaborates with leading transplantation centers and organ procurement organizations worldwide.

Note: VitaSmart is CE marked and available in several markets outside the USA but is not approved for sale in the United States.